Cefazolin MIC Can Serve as a Surrogate for Cephalexin (Keflex) Susceptibility in Urine Isolates
Yes, cefazolin MIC can be used as a surrogate for cephalexin susceptibility in uncomplicated urinary tract infections (uUTIs) caused by E. coli, Klebsiella pneumoniae, and Proteus mirabilis, based on CLSI and USCAST recommendations. However, this surrogacy applies specifically to urine isolates and should not be extrapolated to systemic infections.
The Surrogacy Breakpoint
The Clinical and Laboratory Standards Institute (CLSI) established cefazolin as a more accurate surrogate than the previously used cephalothin for predicting oral cephalosporin susceptibility in uUTIs 1. This change occurred in 2013-2014 after pharmacokinetic/pharmacodynamic (PK/PD) reanalysis demonstrated that cefazolin MIC ≤16 mg/L predicts susceptibility to seven oral cephalosporins, including cephalexin, for the three specified Enterobacteriaceae species 2, 1.
Key Points About the Surrogacy:
- Applies only to uncomplicated UTIs: The high urinary concentrations achieved by oral cephalosporins allow for effective treatment even when systemic breakpoints would suggest resistance 2
- Specific organisms: Valid only for E. coli, K. pneumoniae, and P. mirabilis 1
- Cephalexin dosing: Can be administered as 500 mg twice or thrice daily for uUTIs when the isolate meets cefazolin surrogate criteria 2
Clinical Performance Data
Recent evidence supports the reliability of this surrogacy approach. Among 194 urine isolates, categorical agreement exceeded 95% when using cefazolin to predict oral cephalosporin susceptibility 3. The reanalysis demonstrated that cephalexin achieves very good early bacteriological and clinical cure rates in uUTIs due to non-ESBL Enterobacteriaceae, comparable to traditionally first-line agents 2.
Critical Limitations and Caveats
Not All Oral Cephalosporins Are Equal
Important caveat: While cefazolin surrogacy works well for cephalexin, it does not accurately predict susceptibility for cefadroxil or cephradine 4. These two agents should not be considered equivalent spectrum substitutes despite being oral first-generation cephalosporins 4.
Urinary Tract Only
This surrogacy is strictly limited to urinary tract infections. For bloodstream infections or other systemic infections, different breakpoints apply:
- Systemic cefazolin breakpoint: ≤2 mg/L (susceptible), 4 mg/L (intermediate), ≥8 mg/L (resistant) 5
- Urinary cefazolin surrogate breakpoint: ≤16 mg/L 1
Recent data examining E. coli bacteremia from urinary sources found no difference in 30-day outcomes when patients received oral cephalosporins based on cefazolin MIC ≤2 mg/L versus 4-16 mg/L 6. However, this remains an area requiring further validation, and the standard systemic breakpoints should guide therapy for bacteremia 7.
Practical Implementation
When you receive a urine culture with cefazolin susceptibility testing:
- If cefazolin MIC ≤16 mg/L: Cephalexin is an appropriate fluoroquinolone-sparing option for uUTI in the specified organisms 2
- Dosing: Cephalexin 500 mg PO twice or three times daily for 7 days (per IDSA guidelines for beta-lactams in cystitis) 8, 9
- Do not extrapolate: This surrogacy does not apply to cefadroxil, systemic infections, or organisms outside E. coli, K. pneumoniae, and P. mirabilis
Laboratory Reporting Challenges
Clinical microbiology laboratories face operational challenges implementing this breakpoint, which may cause confusion 1. Some laboratories may report cefazolin results using systemic breakpoints (≤2 mg/L) rather than the urinary surrogate breakpoint (≤16 mg/L), potentially leading to unnecessary use of broad-spectrum antibiotics when cephalexin would be effective for uUTI 1.
Bottom line: Verify with your laboratory which breakpoint they use for urine isolates, and ensure they apply the CLSI urinary surrogate criteria when reporting cephalexin susceptibility predictions.